Venetoclax in combination with low dose Cytarabine and Actinomycin D for primary refractory acute myeloid leukemia patients failing intensive chemotherapy. (December 2021)

• Record Type: Journal Article
• Authors: Daraskevicius, Justinas; Everatt, Veronika; Vaitekenaite, Vilmante; Ringeleviciute, Ugne; Maneikis, Kazimieras; Zucenka, Andrius
• Is Part Of: Leukemia research. Volume 111(2021)
• Publication Date: 2021-12
• Subjects: Leukemia -- Periodicals; Leukemia -- Periodicals; Leucémie -- Périodiques; Leukemia; Periodicals; Electronic journals; Electronic journals; 616.9941905
• DOI: 10.1016/j.leukres.2021.106692
• Languages: English
• ISSNs: 0145-2126

Abstract

Highlights: ACTIVE regimen produced an ORR of 64 % in 15 primary refractory AML patients. 57 % of patients proceeded to allogeneic stem cell transplantation. The median OS was 5.7 months. 3 early deaths were observed in frail patients due to infections and bleeding.